Journals / Toraks Dergisi / 2006 / Cilt: 7 - Sayı: 1

NAT2 (N acetyltransferase-2) genotype in atopic Turkish asthmatics

Atopik astımlı Türklerde NAT2 (N acetyltransferase-2) genotipi

Pages
1–4
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This study suggests that the NAT2 (slow acetylation) genotype is not a marker of predisposition for atopic asthma in the Turkish population.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:It has been shown that slow acetylation may be a risk factor that influences the development of allergic diseases.
📊
Key Findings & Data:N-acetyltransferase2 (NAT2), an enzyme that degrades xenobiotics, carcinogens, and drugs, shows a bimodal distribution of rapid and slow acetylators with broad interethnic variation.
💡
Conclusion & Impact:This study suggests that the NAT2 (slow acetylation) genotype is not a marker of predisposition for atopic asthma in the Turkish population.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Asetiltransferazlar · Aşırı duyarlılık · Türkiye

Abstract

It has been shown that slow acetylation may be a risk factor that influences the development of allergic diseases. N-acetyltransferase2 (NAT2), an enzyme that degrades xenobiotics, carcinogens, and drugs, shows a bimodal distribution of rapid and slow acetylators with broad interethnic variation. It has been reported that there is close correlation between fenotyping and genotyping of NAT2. Homozygous or heterozygous NAT2*4 allelles are known to code for rapid acetylation. It has been known that NAT2 slow acetylation type is a risk factor for allergic diseases. In this case-control study, our aim was to assess the frequency of slow and rapid activity of NAT2 with asthma and asthma severity in the Turkish population. Turkish unrelated atopic subjects with asthma (n=57) and unrelated healthy subjects (n=56) were enrolled in this study. We evaluated two mutations (C282T and T341C) in NAT2 gene. The frequency of slow acetylators inferred from NAT2 genotype was not significantly different in asthmatic subjects (47%) and healthy subjects (43%). No significant association was found between NAT2 genotype and either age, sex, lung function test parameters, disease severity, duration, eosinophilia, serum IgE level within the asthmatics. This study suggests that the NAT2 (slow acetylation) genotype is not a marker of predisposition for atopic asthma in the Turkish population.

Özet

Allerjik hastalıklarda yapılan genetik çalışmalarda yavaş asetilasyonun bir risk faktörü olduğuna dair bilgiler bulunmaktadır. Vücudumuzda NAT2 (Nacetyltransferase2) yavaş ve hızlı olmak üzere iki farklı hızda çalışan; ilaç, xenobiotik ve karsinojenleri metabolize eden bir asetilasyon enzimidir. Bu hız farkı kişinin etnik yapısına göre değişiklik göstermektedir. Yapılan çalışmalarda NAT2 enziminin fenotipi ile genotipi arasında yakın korelasyon olduğu ve NAT2*4 allelinin homozigot veya heterozigot varlığının hızlı asetilasyona yol açtığı bilinmektedir. Günümüzde NAT2 enziminin yavaş asetilasyon tipi olanı allerjik hastalarda daha sık görülmektedir. Bu vakakontrol çalışmasında 57 akraba olmayan Türk atopik astımlı hasta ve 56 akraba olmayan sağlıklı kontrollerde yavaş ve hızlı asetilasyon gösteren NAT2 geninin sıklığının araştırılması amaçlanmıştır. Bu çalışmada NAT2 geninde iki farklı mutasyon (C282T ve T341C) varlığı araştırıldı. Yavaş asetilasyon astımlılarda %47 oranında saptanırken kontrol grubunda %43 hastada saptandı, arada istatistiksel anlamlı fark bulunmadı. Yaş, cinsiyet, eosinofili, solunum fonksiyon testi parametreleri ve serum IgE seviyelerinin bu asetilasyon hızıyla ilişkisi gösterilemedi. Bu çalışmanın sonucunda yavaş asetilasyon genotipinin atopik astımlı Türk hastalarda hastalık gelişmesinde genetik bir yatkınlık olarak saptanamadığı ifade edilebilir.

🔖

Cite This Article

CEYHAN, B., BOURGOS, A., PALMER, L., DRAZEN, J. (2006). NAT2 (N acetyltransferase-2) genotype in atopic Turkish asthmatics. Toraks Dergisi, Cilt: 7 - Sayı: 1, 1–4. https://ajindex.com/articles/368077

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Panhuysen CI, Bleecker ER, Koeter GH et al. Characterization of obstructive airway disease in family members of probands with asthma. An algorithm for the diagnosis of asthma. Am J Respir Crit Care Med 1998;157:1734-42
  2. Bonicke R, Reif W. Enzymatic inactivation of isonicotinic acid hydrizide in human and animal organism. Arch Exp Pathol Pharmacol 1953;220:321-3
  3. Rieder MJ, Shear NH, Kanee A et al. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991;49:13-7
  4. Smith CA, Wadelius M, Gough AC et al. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet 1997;34:758-60
  5. Hein DW, Ferguson RJ, Doll MA et al. Molecular genetics of human polymorphic N-acetyltransferase enzymatic analysis of 15 recombinant wild type, mutant, and chimeric NAT2 allozymes. Hum Mol Genet 1994;2:729-34
  6. Cascorbi I, Brockmoller J, Bauer S et al. NAT2*12A (803A— G) codes for rapid arylamine N-acetylation in humans. Pharmacogenetics 1996;6:257-9
  7. Cascorbi I, Roots I. Pitfalls in N-acetyltransferase2 genotyping. Pharmacogenetics 1999;9:123-7
  8. Vatsis KP, Weber WW, Bell DA et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1-17
  9. Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci USA 1991;88:6333-7
  10. Blum M, Grant DM, McBride W et al. Human arylamine Nacetyltransferase genes, isolation, chromosomal localization and functional expression. DNA Cell Biol 1990;9:193-203
  11. Cascorbi I, Drakoulis N, Brockmoller J et al. Arylamine Nacetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals, correlation with phenotypic activity. Am J Hum Genet 1995;57:581-92
  12. Grant DM. Molecular genetics of the N-acetyltransferases. Pharmacogenetics 1993;3:45-50
  13. Hickman D, Risch A, Camilleri JP, Sim E. Genotyping human polymorphic arylamine N-acetyltransferase, identification of new slow allotypic variants. Pharmacogenetics 1992;2:217-26
  14. Mrozikiewicz PM, Cascorbi I, Brockmoller J, Roots I. Determination and allelic allocation of seven nucleotide transition within the arylamine N-acetyltransferase (NAT2) gene in the Polish population. Clin Pharmacol Ther 1996;59:376-82
  15. Aynacioglu AS, Cascorbi I, Mrozikiewic PM, Roots I. Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population. Pharma